Cancer Family
Embryonal Neoplasm
CI-CAN-00000013Explore in graph →
Non-malignant285 active trials7 approved drugs73 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000013Explore in graph →
Clinical trials
1,126 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06858501 | Comparing 123I-MIBG and 18F-MFBG Imaging in Patients With Newly Diagnosed, High Risk Neuroblastoma | withdrawn | Phase 2 | 0 | Children's Oncology GroupNETWORK | 0 | Sep 16, 2026 | clinicaltrials |
| NCT03647423 | QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma. | withdrawn | Phase 1 / Phase 2 | 0 | ImmunityBio, Inc.INDUSTRY | 1 | Feb 21, 2025 | clinicaltrials |
| NCT06233903 |
| 18F-mFBG Expression in Neural Crest Tumors and Organs Innervated by the Sympathetic Nervous System |
| withdrawn |
| Phase 2 |
| 0 |
| Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)INDUSTRY |
| 1 |
| Jan 21, 2025 |
| clinicaltrials |
| NCT06308575 | A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Jan 10, 2025 | clinicaltrials |
| NCT04791228 | A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors | withdrawn | Phase 2 | 0 | Children's National Research InstituteOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT06182410 | Defibrotide Prophylaxis of Transplant Associated-Thrombotic Microangiopathy for Neuroblastoma | withdrawn | Phase 2 | 0 | University of California, San FranciscoOTHER | 0 | Aug 7, 2024 | clinicaltrials |
| NCT04909515 | Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of Patients With High-Risk Neuroblastoma in First Remission. | withdrawn | Phase 2 | 0 | Y-mAbs TherapeuticsINDUSTRY | 4 | Sep 1, 2022 | clinicaltrials |
| NCT05042934 | Lurbinectedin With or Without Irinotecan in Treating Patients With Relapsed or High Risk Metastatic Ewing Sarcoma | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 10, 2022 | clinicaltrials |
| NCT05116800 | Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma | withdrawn | Phase 2 | 0 | Brown UniversityOTHER | 1 | Dec 7, 2021 | clinicaltrials |
| NCT02689336 | Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors | withdrawn | Phase 2 | 0 | Washington University School of MedicineOTHER | 0 | Sep 9, 2019 | clinicaltrials |
| NCT02011126 | Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors | withdrawn | Phase 2 | 0 | Children's Oncology GroupNETWORK | 0 | Aug 7, 2018 | clinicaltrials |
| NCT03013387 | Dosimetry Guided PRRT With 90Y-DOTATOC | withdrawn | Phase 2 | 0 | Sue O'DorisioOTHER | 0 | Aug 25, 2017 | clinicaltrials |
| NCT01048086 | 90Y DOTA/Retinoic Acid for Neuroblastoma and Neuroendocrine Tumor (NET) | withdrawn | Phase 2 | 0 | University of IowaOTHER | 1 | Jun 21, 2016 | clinicaltrials |
| NCT00003273 | Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor | withdrawn | Phase 2 | 0 | NYU Langone HealthOTHER | 3 | Dec 3, 2015 | clinicaltrials |
| NCT00992173 | Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma | withdrawn | Phase 2 | 0 | Molecular Insight Pharmaceuticals, Inc.INDUSTRY | 2 | Nov 26, 2015 | clinicaltrials |
| NCT00874315 | Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory High-Risk NBL. | withdrawn | Phase 2 | 0 | Nationwide Children's HospitalOTHER | 1 | Oct 16, 2015 | clinicaltrials |
| NCT01174537 | New Castle Disease Virus (NDV) in Glioblastoma Multiforme (GBM), Sarcoma and Neuroblastoma | withdrawn | Phase 1 / Phase 2 | 0 | Hadassah Medical OrganizationOTHER | 1 | Jun 11, 2015 | clinicaltrials |
| NCT00389766 | High-Dose Iodine I 131 Metaiodobenzylguanidine, Topotecan, and Peripheral Stem Cell Transplant in Treating Young Patients With Relapsed Stage 4 Neuroblastoma or Primary Resistant High-Risk Neuroblastoma | withdrawn | Phase 2 | 0 | Children's Cancer and Leukaemia GroupOTHER | 0 | Jul 10, 2013 | clinicaltrials |
Data updated 14 days agoSource updated Sep 16, 2026source: clinicaltrials